Horizon Pharma plans to price public offering of common-share units

Company sells units through Cowen, JMP and Stifel Nicolaus Weisel

By Devika Patel

Knoxville, Tenn., Sept. 19 - Horizon Pharma, Inc. will price a public sale of its units, according to a prospectus supplement filed Wednesday with the Securities and Exchange Commission.

The units will consist of one common share and a half-share warrant. The whole warrants will be exercisable for five years.

Cowen and Co., JMP Securities and Stifel Nicolaus Weisel are the joint bookrunners.

Proceeds will be used for commercialization activities and other general corporate purposes, including research and development, general and administrative expenses, manufacturing and potential acquisitions.

Horizon is a Northrook, Ill., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.